Too much information and not sure what to do? Start here.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating indiv idual securities.
If you wish to go to ZacksTrade, click
OK. If you do not, click Cancel.
Back to top
Covidien Unveils Advanced Ablation Device for Liver Tumor
Aiming to capitalize on the opportunities in the inoperable liver cancer market,
Covidien plc unveiled Emprint Ablation System with Thermosphere Technology – an advanced ablation system designed to precisely heat and destroy diseased soft tissue in the liver, lungs and kidney.
The Emprint Ablation System enables physicians to deliver precise ablation directly to soft tissue, including liver tumors. This innovative technology ensures more certainty regardless of the target location or tissue type, thus making liver tumor ablation more accurate.
Covidien’s Ablation System provides clinicians with three kinds of spatial energy control – thermal, field and wavelength. This helps them to create predictable and spherical ablation zones regardless of target location, tissue type or changes in tissue properties during a procedure.
By providing predictable spherical ablation zones, this technology offers physicians more choices in terms of approach, further simplifying needle placement and saving planning and procedure time.
A liver tumor ablation procedure destroys the tumor without removing it, thus providing an alternative to open surgery resection or other treatments. This method is ideal for patients for whom surgical removal of tumors is not an optimal solution.
With Covidien’s Ablation System, physicians can treat liver tumor by non-surgical procedures. They utilize ultrasound or CT scanning to guide the system’s antenna and insert it directly into the tumor through the skin. Apart from non-surgical procedures, Covidien’s advanced ablation system can also be used for minimally invasive surgery and open surgery.
In Apr 2014, Covidien received the U.S. Food and Drug Administration 510(k) clearance for its Emprint Ablation System. In addition, the company completed all European requirements for attaining the CE Mark for the product. Covidien expects to fully launch the Emprint Ablation System in the U.S. and the European Union in the present quarter.
Currently, Covidien carries a Zacks Rank #4 (Sell). Better-ranked stocks in the medical products industry include Alere Inc. ( ALR - Snapshot Report) , CareFusion Corporation and Wright Medical Group Inc. ( WMGI - Analyst Report) . All these stocks carry a Zacks Rank #2 (Buy).